JAZZ

Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021

Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021

Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze

Jazz's leukemia drug gets approved by the FDA

Jazz Pharma's Rylaze Scores FDA Approval For Blood Cancer

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution